83 related articles for article (PubMed ID: 7075043)
1. Weight loss during therapy for advanced breast cancer.
Rowland-Payne CM; Abbott M; Jones JM; Powles TJ; Coombes RC
Clin Oncol; 1982 Mar; 8(1):33-8. PubMed ID: 7075043
[No Abstract] [Full Text] [Related]
2. Combination therapy with progestins and tamoxifen in advanced breast cancer: A preliminary report.
Trodella L; Ausilli-Cefaro GP; Turriziani A; Saccheri S; Venturo I; Minotti G
Am J Clin Oncol; 1982 Oct; 5(5):495-9. PubMed ID: 6217741
[No Abstract] [Full Text] [Related]
3. New regimen of combination hormone therapy (ME-TA-MAP) in the treatment of advanced breast cancer. A pilot study.
Pannuti F; Martoni A; Fruet ; Marraro D; Strocchi E
Panminerva Med; 1981; 23(3):157-60. PubMed ID: 7335366
[No Abstract] [Full Text] [Related]
4. Tamoxifen: a brief review.
Reich SD
Cancer Nurs; 1981 Aug; 4(4):319-20. PubMed ID: 6911059
[No Abstract] [Full Text] [Related]
5. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
6. Dibromodulcitol and adriamycin +/- tamoxifen in advanced breast cancer.
Tormey DC; Falkson G; Crowley J; Falkson HC; Voelkel J; Davis TE
Am J Clin Oncol; 1982 Feb; 5(1):33-9. PubMed ID: 7081136
[TBL] [Abstract][Full Text] [Related]
7. [Chemotherapy in advanced breast cancer: experience in 100 cases (author's transl)].
Modolell Roig A; Sans-Sabrafen J; Pardo Peret P; Rodríguez Ferrera JC; Boleda Relats M; Buxó Costa J; Galofré Folch M
Med Clin (Barc); 1982 Mar; 78(6):211-7. PubMed ID: 7087579
[No Abstract] [Full Text] [Related]
8. Combination chemotherapy in advanced breast cancer. A report of the Working Party of the Multicentre Cancer Chemotherapy Group.
Spittle MF; Bates TD; Kitchen G; Nicol NT; Wheeler T; Edelstyn G; MacRae KD; Ostrowski MJ
Clin Oncol; 1980 Jun; 6(2):153-7. PubMed ID: 7408282
[No Abstract] [Full Text] [Related]
9. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy and tamoxifen for breast cancer.
N Engl J Med; 1981 Oct; 305(17):1014-5. PubMed ID: 7278914
[No Abstract] [Full Text] [Related]
11. [Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Illiger HJ
Strahlenther Onkol; 2002 Feb; 178(2):111-3. PubMed ID: 11942036
[No Abstract] [Full Text] [Related]
12. [Chemotherapy in breast cancer].
Hoang Palangie T
Soins Gynecol Obstet Pueric; 1981 May; (4):19-22. PubMed ID: 6910911
[No Abstract] [Full Text] [Related]
13. [Effect of antiblastic polychemotherapy (CMF) on the number of circulating monocytes in patients with breast cancer].
Bariani L; Dolcetti U; Indelli M; Gualandi G; Malacarne P; Castaldi G
Minerva Med; 1982 Oct; 73(39):2641-8. PubMed ID: 7121879
[TBL] [Abstract][Full Text] [Related]
14. [A study on the efficacy of combination chemoendocrine therapy consisting of cyclophosphamide, adriamycin, UFT, and tamoxifen for advanced or recurrent breast cancer].
Yamaguchi S; Fukuda M; Ota T; Nakayama Y; Ogata H; Shimizu K; Nishikawa T; Adachi Y; Fukuma E
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1145-52. PubMed ID: 10431580
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer].
Mitsuyama S; Tashiro H; Koga T; Maehara Y; Ogawa M; Kakegawa T; Shimazu H; Sugimachi K; Tomita M; Nakamura Y
Gan To Kagaku Ryoho; 1995 Dec; 22(14):2073-80. PubMed ID: 8607618
[TBL] [Abstract][Full Text] [Related]
16. Weight gain and adjuvant chemotherapy.
Knobf MK
Oncol Nurs Forum; 1985; 12(6):13. PubMed ID: 3851446
[No Abstract] [Full Text] [Related]
17. No predisposition to herpes zoster with chemotherapy of breast cancer.
Markman M; Abeloff MD
N Engl J Med; 1981 Mar; 304(13):789. PubMed ID: 7464891
[No Abstract] [Full Text] [Related]
18. Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Needleman SJ; Tobias JS
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1871-81. PubMed ID: 19046107
[TBL] [Abstract][Full Text] [Related]
19. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM
Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
[TBL] [Abstract][Full Text] [Related]
20. [Effects of combined hormone therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer].
Fukutomi T; Adachi I; Watanabe T; Nanasawa T; Yamamoto H
Gan To Kagaku Ryoho; 1993 May; 20(7):957-9. PubMed ID: 8489302
[No Abstract] [Full Text] [Related]
[Next] [New Search]
